Literature DB >> 1768791

Tumor cell lysis and tumor growth inhibition by the isotype variants of MAb BR55-2 directed against Y oligosaccharide.

Z Steplewski1, M D Lubeck, D Scholz, H Loibner, J McDonald Smith, H Koprowski.   

Abstract

IgG3 murine MAb BR55-2 is directed against adenocarcinoma associated Y oligosaccharide. Isotype IgG1, IgG2b and IgG2a switch variants of the BR55-2 antibody were compared in antibody dependent-cell mediated cytotoxicity (ADCC) and complement mediated cytotoxicity (CDC) assays in the murine system. IgG3, IgG2a and IgG2b isotypes mediated ADCC with murine macrophages. Murine splenocytes mediated low levels of ADCC, with IgG3 and IgG2a being always more effective than IgG1 and IgG2b isotypes. All four isotypes were ineffective in CDC with murine serum as a source of complement. In the in vivo experiments, growth of human tumors xenotransplanted into nude mice was best inhibited by both IgG3 and IgG2a isotypes while IgG1 protein was the least effective. Thus, IgG3 and IgG2a isotypes are the most efficient proteins for cancer immunotherapy since they mediate the highest tumoricidal activities in vitro and in vivo.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1768791

Source DB:  PubMed          Journal:  In Vivo        ISSN： 0258-851X            Impact factor:   2.155


  7 in total

1.  Biological activity in the human system of isotype variants of oligosaccharide-Y-specific murine monoclonal antibodies.

Authors:  D Scholz; M Lubeck; H Loibner; J McDonald-Smith; Y Kimoto; H Koprowski; Z Steplewski
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  The Potential Role of Solvation in Antibody Recognition of the Lewis Y Antigen.

Authors:  Somdutta Saha; Ramachandran Murali; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-10

3.  Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells.

Authors:  Robert Brodzik; Magdalena Glogowska; Katarzyna Bandurska; Monika Okulicz; Deepali Deka; Kisung Ko; Joke van der Linden; Jeanette H W Leusen; Natalia Pogrebnyak; Maxim Golovkin; Zenon Steplewski; Hilary Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-23       Impact factor: 11.205

Review 4.  Antibodies: At The Nexus of Antigens and Cancer Vaccines.

Authors:  Zenon Steplewski; Magdalena Thurin; Thomas Kieber-Emmons
Journal:  J Infect Dis       Date:  2015-07-15       Impact factor: 5.226

5.  Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer.

Authors:  R H Brakenhoff; F B van Gog; J E Looney; M van Walsum; G B Snow; G A van Dongen
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

6.  Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients.

Authors:  M V Croce; M Isla-Larrain; R Tur; M E Rabassa; A Segal-Eiras
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects.

Authors:  Laura F Hutchins; Issam Makhoul; Peter D Emanuel; Angela Pennisi; Eric R Siegel; Fariba Jousheghany; Xueyan Guo; Anastas D Pashov; Behjatolah Monzavi-Karbassi; Thomas Kieber-Emmons
Journal:  Oncotarget       Date:  2017-10-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.